• Work With Us
    • Partnerships
      • We offer tailored partnerships to support and transform drug discovery.

        Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

    • Services
      • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

        As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

    • OrganoReady®
      • Our OrganoReady program is made for you when you need defined assays in ADME.

        We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Resources & Support
    • Knowledge Center
      • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

    • Blogs
      • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
    • Case Studies
      • Get inspired by research done by our scientists, partners, and customers around the globe.

    • Webinars & Events
    • Applications
  • About MIMETAS
  • News
  • We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need defined assays in ADME.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

Human BBB-on-a-chip reveals barrier disruption, endothelial inflammation, and T cell migration under neuroinflammatory conditions

Leiden, September 14, 2023 – MIMETAS Scientists established a high-throughput human BBB-on-a-chip to study neuroinflammation and transendothelial migration.

The blood-brain barrier (BBB) serves as a physiological and metabolic barrier that ensures a homeostatic environment for a healthy functioning of the central nervous system (CNS). This protective function of the BBB is challenged in neurological conditions, such as stroke and multiple sclerosis (MS), resulting in neuroinflammation, which in turn exacerbates disease progression. To investigate neuroinflammatory disorders, researchers have traditionally relied on animal models and transwell-based blood-brain barrier (BBB) models. Recapitulation of the intricate pathogenesis, clinical evolution, and disease variability seen in patients has consistently posed a challenge when using those traditional models. To bridge this gap and achieve a closer mimicry of human disease progression, more advanced in vitro microfluidic models, such as our innovative 3D tissue models, offer a promising solution.

In this work, MIMETAS scientists developed a human BBB-on-a-chip to study neuroinflammation and transendothelial migration (TEM). This model comprises of primary human brain microvascular endothelial cells (HBMECs) cultivated under bidirectional perfusion. To mimic an inflammatory environment, pro-inflammatory cytokines were used. The researchers found that exposure to these cytokines led to a concentration-dependent disruption of the BBB. Furthermore, it induced noticeable alterations in the morphology of endothelial cells. Notably, the researchers also found an upregulation in the expression of critical cell adhesion molecules, ICAM-1 and VCAM-1 by HBMECs. An augmented migration of T cells into the basolateral compartment was also observed in response to these inflammatory conditions. The study further shows that T cell adhesion and migration was decreased in the presence of Natalizumab, an anti-VLA4 monoclonal antibody that is used to treat MS.

Taken together, the development of this high-throughput, membrane-free microfluidic BBB-on-a-chip model provides a valuable tool for studying neuroinflammation and the evaluation of potential therapeutic strategies. Its advanced imaging capabilities also make it ideal for investigating drug candidates aimed at reducing immune cell infiltration and facilitating BBB restoration.


Read the publication Sign up for our Newsletter

Cookies

‘May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy

Accept all
Accept selected
Decline all